Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2014-09-01 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
独立董事关于公司与关联方共同设立投资管理公司的关联交易事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors regarding a related party transaction involving the establishment of an investment management company jointly with an affiliated party. It discusses the legality, fairness, and strategic rationale of the transaction. There are no financial statements, no report publication, no voting results, no management changes, no earnings data, and no regulatory certifications. The document is a formal opinion related to corporate governance and compliance with listing rules and regulations. This fits best under Regulatory Filings (RNS), as it is a regulatory announcement related to a related party transaction and independent director opinion, but not a full report or financial statement.
2014-09-01 Chinese
关于与关联方共同设立投资管理公司的关联交易公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by the company 中源协和干细胞生物工程股份公司 regarding a related party transaction involving the establishment of an investment management company jointly with an affiliated party 银宏（天津）股权投资基金管理有限公司. It details the transaction background, parties involved, capital contributions, governance structure, and independent directors' opinions. The document is an announcement of a corporate transaction related to capital investment and related party dealings, not a financial report, earnings release, or regulatory certification. It does not contain financial statements or detailed financial analysis. The content fits best under Capital/Financing Update (CAP) as it concerns company fundraising and capital structure changes through the establishment of a new investment management company with related parties.
2014-09-01 Chinese
第八届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolution from the company's board meeting regarding the granting of restricted stock under a stock incentive plan. It details the approval process, conditions, and voting results related to the stock incentive plan. There are no financial statements or comprehensive financial data presented. The document is a formal announcement of a board decision, specifically about management and board matters related to stock incentives. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and it is not a report or a regulatory filing but a board resolution announcement.
2014-08-22 Chinese
北京道淳律师事务所关于干细胞生物工程股份公司限制性股票激励计划股票授予相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the stock grant under a restricted stock incentive plan of a company. It discusses the approval and authorization of the stock grant by the board, the grant date, adjustments to the number of shares and recipients, and the fulfillment of grant conditions. It references relevant laws and regulations but does not contain financial statements or performance data. The document is a standalone legal opinion related to a stock incentive plan, not a financial report, earnings release, or management discussion. It is not an announcement of a report but a legal opinion letter. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers miscellaneous filings that do not fit other categories, including legal opinions and compliance documents.
2014-08-22 Chinese
2014年限制性股票激励计划激励对象名单
Remuneration Information Classification · 95% confidence The document is titled '2014 年限制性股票激励计划激励对象名单' which translates to '2014 Restricted Stock Incentive Plan Incentive Object List'. It lists individuals and their stock awards under a stock incentive plan, including positions and stock quantities. This is a detailed disclosure of stock awards to management and key personnel, which aligns with disclosures related to remuneration or compensation information. The document is not a full annual report, earnings release, or other financial report. It is not a proxy solicitation or voting result announcement. It is a detailed report on stock incentives, which fits best under Remuneration Information (DEF 14A) category, as it relates to executive and key personnel compensation through stock incentives. The document length is 2858 characters, which is consistent with a detailed remuneration disclosure rather than a brief announcement or a full report. Therefore, the classification is DEF 14A with high confidence.
2014-08-22 Chinese
第八届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company 中源协和干细胞生物工程股份公司 regarding the verification of the list of stock incentive recipients. It details the meeting date, attendance, and the approval of the agenda item related to stock incentive eligibility. There is no financial data, no mention of annual or interim reports, no earnings data, no voting results from a general meeting, and no mention of changes in board or management. The document is a formal announcement of a board meeting resolution related to internal governance and compliance with stock incentive regulations. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement that does not fit other specific categories like MANG or DVA.
2014-08-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.